Join our daily newsletter At The Bell to receive exclusive market insights
- Proteomics International Laboratories (PIQ) has produced a pilot batch of PromarkerD test components to predict the onset of diabetic kidney disease
- The products were produced through a collaboration with specialist immunoassay manufacturer Biotem
- Through the partnership, Biotem completed the transfer of the manufacturing process and produced key components to assemble over 50,000 PromarkerD tests
- The tests were manufactured for quality control and regulatory testing and will also form part of Proteomics’ inventory for its initial sales
- Proteomics International last traded at 83 cents on June 15
Proteomics International Laboratories (PIQ) has produced a pilot batch of PromarkerD test components to predict the onset of diabetic kidney disease.
The products were produced through a collaboration with specialist immunoassay manufacturer Biotem.
The partnership between the two companies began in August last year when Proteomics contracted Biotem to manufacture the immunoassay kit version of PromarkerD.
Through the partnership, Biotem has now completed the transfer of the manufacturing process and produced key components to assemble over 50,000 PromarkerD tests.
Proteomics Managing Director Richard Lipscombe said the pilot production run was a big step in demonstrating the technology transfer required for large-scale global distribution.
“Working with a specialist manufacturer like Biotem allows us to build our production capacity to meet the anticipated demand for PromarkerD in the northern hemisphere and worldwide,” Dr Lipscombe said.
The tests were manufactured for quality control and regulatory testing and will also form part of Proteomics’ inventory for its initial sales.
PromarkerD is a prognostic test that can predict future kidney function decline in patients with either type two diabetes or no existing diabetic kidney disease whatsoever.
The test is used to identify a unique “fingerprint” of protein biomarkers in the blood using specialist antibodies, which is then used by an algorithm to integrate the results into a patient risk report.
Proteomics International last traded at 83 cents on June 15.
